Research Analysts Offer Predictions for PepGen Q1 Earnings

PepGen, Inc. (NASDAQ:PEPG) – Analysts at HC Wainwright increased their Q1 2026 EPS estimates for PepGen in a research note issued to investors on Thursday, March 5th. HC Wainwright analyst A. Ghosh now anticipates that the company will post earnings of ($0.27) per share for the quarter, up from their prior forecast of ($0.52). HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for PepGen’s current full-year earnings is ($2.73) per share. HC Wainwright also issued estimates for PepGen’s Q2 2026 earnings at ($0.27) EPS, Q3 2026 earnings at ($0.27) EPS, Q4 2026 earnings at ($0.27) EPS, FY2026 earnings at ($1.09) EPS, FY2027 earnings at ($1.88) EPS, FY2028 earnings at ($1.82) EPS, FY2029 earnings at ($1.43) EPS and FY2030 earnings at ($0.66) EPS.

Other analysts have also issued reports about the company. Wall Street Zen raised PepGen from a “sell” rating to a “hold” rating in a research note on Saturday, November 15th. Oppenheimer initiated coverage on PepGen in a research note on Wednesday, February 25th. They issued an “outperform” rating and a $15.00 price objective for the company. Guggenheim lifted their target price on shares of PepGen from $6.00 to $7.00 and gave the stock a “buy” rating in a research note on Wednesday, February 18th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of PepGen in a report on Thursday, January 22nd. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, PepGen presently has an average rating of “Moderate Buy” and a consensus target price of $12.60.

PepGen Trading Up 3.1%

NASDAQ:PEPG opened at $5.68 on Monday. The stock has a 50 day moving average of $5.91 and a two-hundred day moving average of $4.78. PepGen has a 12 month low of $0.88 and a 12 month high of $7.80. The firm has a market cap of $392.54 million, a P/E ratio of -2.36 and a beta of 1.86.

PepGen (NASDAQ:PEPG) last issued its quarterly earnings results on Wednesday, March 4th. The company reported ($0.27) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.13.

Hedge Funds Weigh In On PepGen

A number of institutional investors have recently added to or reduced their stakes in the stock. Rangeley Capital LLC boosted its stake in PepGen by 133.3% during the second quarter. Rangeley Capital LLC now owns 35,000 shares of the company’s stock worth $39,000 after buying an additional 20,000 shares during the last quarter. Marshall Wace LLP acquired a new position in PepGen in the second quarter valued at approximately $44,000. Heights Capital Management Inc. acquired a new position in PepGen in the third quarter valued at approximately $46,000. Burkehill Global Management LP purchased a new position in PepGen in the third quarter worth approximately $46,000. Finally, Militia Capital Partners LP acquired a new stake in PepGen during the third quarter worth $72,000. Hedge funds and other institutional investors own 58.01% of the company’s stock.

PepGen Company Profile

PepGen, Inc (NASDAQ: PEPG) is a clinical-stage biotechnology company headquartered in San Diego, California. The company is developing precision gene editing therapies to address rare genetic diseases by combining advanced prime editing modalities with proprietary delivery technologies. PepGen’s platform is designed to achieve targeted and durable correction of disease-causing mutations in vivo, with the goal of providing long-lasting therapeutic benefit after a single administration.

The company’s lead development programs include PPG-001 for mucopolysaccharidosis type II (Hunter syndrome) and PPG-002 for mucopolysaccharidosis type I (Hurler syndrome).